Eli Lilly Sues Six Firms Over Black-Market Retatrutide Sales
LLY sits 94% above its 52-week low of $629.398.
Summary
Lilly filed six lawsuits against compounding pharmacies, med spas, and online sellers for unauthorized retatrutide sales. The company has referred over 200 entities to regulators and cites CBP seizures of illicit GLP-1 drugs. This escalates enforcement ahead of retatrutide's potential approval, protecting a key pipeline asset. The action signals Lilly's aggressive defense of its obesity franchise amid booming demand.
At the time of this announcement, LLY was trading at $1,221.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $629.40 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.